+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05978193

Phase II Study of First-line PD-1 Inhibitor and Chemotherapy With or Without Radiotherapy for Metastatic Esophageal Squamous Cell Carcinoma

Led by Shanghai Chest Hospital · Updated on 2026-01-22

100

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the potential benefits of combining low-dose radiotherapy LDRT and conventionally fractionated radiotherapy CFRT with first-line anti-PD-1 immunochemotherapy in treating metastatic esophageal squamous cell carcinoma ESCC. This phase II multicenter study aims to evaluate the safety, feasibility, and effectiveness of this combined approach compared to standard immunochemotherapy alone. The study begins with a safety run-in phase to ensure treatment safety before proceeding to a randomized controlled phase. The study has two phases Phase IIa is a safety run-in where about 20-25 patients receive the combination of LDRT, CFRT, and immunochemotherapy to assess safety and feasibility. If safety criteria are met, Phase IIb randomly assigns participants to either an experimental group receiving PD-1 inhibitor plus chemotherapy with LDRT and CFRT, or a control group receiving PD-1 inhibitor plus chemotherapy alone. Treatments include PD-1 inhibitors given every three weeks, chemotherapy with paclitaxel and platinum agents over four cycles, and specific radiotherapy dosing schedules targeting tumors and metastatic lesions. Participants will be closely monitored through regular assessments including safety evaluations up to 30 days after treatment, and progression-free survival up to 36 months after randomization. Researchers will also track overall survival and the incidence of severe treatment-related side effects over one year. The study aims to understand how adding radiotherapy affects treatment outcomes and safety in metastatic ESCC, with ongoing observation throughout the study period.

CONDITIONS

Brief Title

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Research Team

W

Wen Yu, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here